CurrentOscar HealthPolicy N/A

Vitamin D Testing

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity, coverage limitations, and testing methods for serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D testing for Oscar Health members.

Policy Summary

PayerOscar Health

PolicyVitamin D Testing (coverage criteria for 25‑OH and 1,25‑dihydroxyvitamin D testing)

Policy CodePolicy N/A

Change TypeAdministrative — no material clinical changes

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

Key ActionOrder vitamin D testing only when clinical indications are documented and limit repeat 25(OH)D testing to no more than one test every six months, with retesting generally not sooner than 3 months after therapy initiation.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1/6momax frequency (25‑OH)

3 mominimum retest interval

<20 ng/mLdeficiency threshold

~20%LC‑MS/MS use

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentOscar HealthPolicy N/A

Vitamin D Testing

Customize your policy alerts

Sign up for all Oscar Health policy alerts

Know when Oscar Health releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines medical necessity, coverage limitations, and testing methods for serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D testing for Oscar Health members.

Policy Summary

PayerOscar Health

PolicyVitamin D Testing (coverage criteria for 25‑OH and 1,25‑dihydroxyvitamin D testing)

Policy CodePolicy N/A

Change TypeAdministrative — no material clinical changes

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1/6momax frequency (25‑OH)

3 mominimum retest interval

<20 ng/mLdeficiency threshold

~20%LC‑MS/MS use

retrospective study tests

Coverage Criteria

25-hydroxyvitamin D (25OHD) testing

Covered when ALL of the following are met for 25-hydroxyvitamin D testing:

General: Testing is covered for individuals with an underlying disease/condition specifically associated with vitamin D deficiency, for individuals suspected of hypervitaminosis D, or for individuals with vitamin D deficiency.no more than one test every six months

See Note 1 for covered indications list.

D2 and D3 fraction testing

Covered when performed as part of total 25-hydroxyvitamin D analysis:

Fraction testing: Testing for D2 and D3 fractions of 25-hydroxyvitamin D meets criteria when performed as part of the total 25OHD analysis.

1,25-dihydroxyvitamin D testing

Covered when ALL of the following are met for 1,25-dihydroxyvitamin D testing:

Metabolism defects: Serum 1,25-dihydroxyvitamin D testing meets criteria for evaluation or treatment of conditions associated with defects in vitamin D metabolism.

See Note 2 for indications list.

Not medically necessary / Not covered

Not covered: Measurement of serum 1,25-dihydroxyvitamin D to screen for vitamin D deficiency OR routine screening for vitamin D deficiency in asymptomatic individuals and/or during general encounters.

These testing indications do not meet criteria.

Medically necessary/appropriate testing scenarios

Covered when testing is for clinically justified indications or monitoring in at‑risk patients. Examples include:

At‑risk clinical conditions: Testing indicated for patients with conditions affecting vitamin D metabolism or status (malabsorption syndromes, undernourishment, eating disorders, candidates for bariatric surgery, renal or liver disease, multiple myeloma, sarcoidosis, hyper/hypoparathyroidism, organ transplant recipients, diseases with low sun exposure, vitamin D inborn errors)

supported by clinical conditions list

Bone disease or osteoporosis management: Measure serum 25(OH)D in patients at risk for insufficiency particularly those with osteoporosis or bone disease, and prior to/when planning specific bone treatments; aim to maintain levels per endocrinology guidance (AACE/ACE recommend ≥30 ng/mL in osteoporosis)AACE/ACE: ≥30 ng/mL

guideline support in chunks 34 and 30

Medication or therapy monitoring: Testing indicated when pharmacotherapy increases vitamin D catabolism (antiseizure drugs, glucocorticoids), in patients receiving treatment for AIDS or tuberculosis, and for monitoring vitamin D replacement in select patients

Repeat testing guidance

Repeat vitamin D measurement is generally not recommended except in specific clinical situations.

Repeat testing allowed when ALL of the following apply: Repeat Vitamin D measurement should only be considered in patients who meet at least one of: (1) had symptomatic Vitamin D deficiency (e.g. hypocalcaemia or bone disease); (2) have malabsorption and are taking Vitamin D; (3) are on oral anti-resorptive agents and had low baseline Vitamin D levels.not within 3 months (preferably not within 6 months)

Repeat testing should not be done within three months of the initial test, and preferably not within six months.

Testing vs empiric treatment for asymptomatic high-risk individuals

Recommendation from referenced trust regarding high-demand testing reduction.

Empiric treatment option: Asymptomatic individuals at high risk of Vitamin D deficiency should be treated without measurement of vitamin D and advised on maintenance supplementation.

Guidance aims to reduce unnecessary testing workload.

Routine screening for vitamin D deficiency with serum testing in asymptomatic individuals or during general encounters is excluded from coverage. Measurement of serum 25-hydroxyvitamin D for the purpose of population-level or opportunistic screening does not meet criteria in the absence of a documented clinical indication.

Routine population screening of asymptomatic individuals is not supported. Major guideline panels—including The Endocrine Society, the USPSTF, and the American Academy of Pediatrics—recommend against routine 25(OH)D screening in the general adult population (including different adult age groups), during pregnancy, and in otherwise healthy children without conditions affecting bone health. Screening of these populations is therefore excluded unless a specific clinical indication is documented.

Repeat vitamin D testing is excluded for the majority of patients and should be avoided without clinical justification. Per the cited guidance, repeat measurement should not be performed within three months of an initial test and is preferably deferred until at least six months in most patients unless one of the specified clinical indications for retesting applies.

Measurement of serum 1,25-dihydroxyvitamin D for the purpose of screening for vitamin D deficiency is not medically necessary and does not meet coverage criteria. 1,25-dihydroxyvitamin D testing is reserved for evaluation of specific disorders of vitamin D metabolism rather than routine status assessment.

Routine measurement of serum 25-hydroxyvitamin D (25[OH]D) for screening in the general population is not supported by the evidence and is excluded. Multiple guideline sources conclude there is insufficient evidence of benefit for population-based screening (including adults across age groups, pregnant individuals, and healthy children), so routine 25(OH)D testing in asymptomatic persons is not covered absent an accepted clinical indication.

Routine repeat measurement of 25(OH)D is generally not recommended. Repeat testing may be considered only for narrowly defined clinical scenarios (for example, symptomatic deficiency, malabsorption on replacement therapy, or patients on anti-resorptive therapy with low baseline levels). When repeat testing is indicated, it should not be done within three months of initiating therapy and is preferably deferred until at least six months in most patients.

Indications for Testing (Covered)

List of specific disorders/conditions where serum 25OHD or 1,25-dihydroxyvitamin D testing is indicated (see Note 1 and Note 2)

See Note 1 and Note 2 for specific listed disorders/conditions where serum 25OHD or 1,25-dihydroxyvitamin D testing is indicated:

Selected indications (25OHD): Biliary cirrhosis; blind loop syndrome; celiac disease; coronary artery disease when considering chronic vitamin D therapy; dermatomyositis; eating disorders; bariatric surgery candidates or postoperative; disorders of calcium metabolism (hypercalcemia, hypocalcemia); hyperparathyroidism or hypoparathyroidism; individuals receiving hyperalimentation; inflammatory bowel disease; intestinal malabsorption; liver cirrhosis; long-term use of anticonvulsants, glucocorticoids, chemotherapy; malnutrition; myositis/myopathy; neoplastic hematologic disorders; osteogenesis imperfecta; osteomalacia; osteopetrosis; osteoporosis; pancreatic steatorrhea; tuberculosis; psoriasis; regional enteritis; renal/urinary calculus; rickets; sarcoidosis; stage III–V CKD and ESRD; systemic lupus erythematosus.

Derived from Note 1 (chunk 5)

Selected indications (1,25-dihydroxyvitamin D): Disorders of calcium metabolism; familial hypophosphatemia; Fanconi syndrome; hyperparathyroidism or hypoparathyroidism; individuals receiving hyperalimentation; neonatal hypocalcemia; osteogenesis imperfecta; osteomalacia; osteopetrosis; tuberculosis; renal/urinary calculus; rickets; sarcoidosis; stage III–V CKD and ESRD.

Derived from Note 2 (chunk 6)

Testing Frequency and Retest Intervals

25-hydroxyvitamin D serum testing — frequency limit

Maximum tests allowed1 test per 6 months

Serum 25‑hydroxyvitamin D — retest timing guidance

Retest minimum intervalDo not retest within 3 months of initiating supplementation

Preferred retest intervalPrefer not to retest within 6 months in most patients

Laboratory consistencyIf retesting after 3 months, use the same laboratory when possible

Vitamin D measurement — repeat testing policy

Coding and Definitions

Referenced CPT/Proprietary codesCPT

82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed.
82652	Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed.
0038U	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative (Proprietary test: Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay)

Vitamin D deficiency threshold

Deficiency threshold25OHD < 20 ng/mL

Insufficiency referenceSome organizations consider <30 ng/mL as insufficient

IOM recommended rangeMaintain serum 25OHD between 20 and 40 ng/mL

Provider Actions, Documentation, and Billing

Prior Authorization

Prior authorization / coverage condition for 25‑OH testing

25-hydroxyvitamin D (25‑OH) serum testing meets coverage criteria only for individuals with an underlying disease/condition specifically associated with vitamin D deficiency or decreased bone density, for suspected hypervitaminosis D, or for individuals with documented vitamin D deficiency; testing is limited to no more than one test every six months.

Coverage applies when indications listed in Note 1 are present (see policy Notes).

Step Therapy

Retest timing requirement — minimum interval

Do not perform repeat 25(OH)D testing within three months of initiating vitamin D replacement; many guideline sources recommend waiting at least three months and preferably up to six months before retesting.

RACGP: “Do not retest vitamin D levels within three months of the patient beginning to take vitamin D replacement.”
Manchester NHS: “Repeat testing should not be done within three months of the initial test, and preferably not within six months.”

Ordering Requirements

Prior Authorization

Ordering must be based on documented clinical indication and medical necessity

Order vitamin D testing only when there is documented clinical indication and medical necessity; appropriateness may be evaluated against the policy's listed indications.

Step Therapy

Consider empiric supplementation for asymptomatic high‑risk individuals

Consider empiric vitamin D supplementation without measurement for asymptomatic high‑risk individuals per some NHS/Manchester guidance; otherwise, ordering should follow documented indications in the policy.

Documentation Required

Document the clinical indication when ordering vitamin D tests

Follow clinical guidance when ordering tests and ensure documentation reflects the specific indication (for example, symptomatic deficiency, malabsorption, or monitoring during anti‑resorptive therapy).

Not Covered Services

Routine population screening of asymptomatic individuals and the use of serum 1,25-dihydroxyvitamin D to screen for deficiency are not covered. 1,25-dihydroxyvitamin D testing meets criteria only for evaluation of specific metabolic disorders described elsewhere in the policy.

Routine vitamin D screening/testing in asymptomatic members of the general population—including pregnant individuals and otherwise healthy children without bone disease—is not covered. Major guideline bodies advise against universal screening; testing should be reserved for documented clinical indications outlined in the policy.

Routine repeat vitamin D testing in the majority of patients is not covered. Repeat measurement should only be considered for the limited clinical situations enumerated in the policy, and testing within three months (preferably within six months) of the prior result is excluded.

Definitions

25(OH)D — definition

Term25(OH)D = 25-Hydroxyvitamin D

UsePrimary nomenclature used in the policy terminology table

SynonymInterchangeable with '25OHD' per policy terminology

25OHD — definition

Term25OHD = 25-Hydroxyvitamin D

Common reporting unitsng/mL (nmol/L conversion noted in background)

Clinical rolePreferred test to evaluate vitamin D status (primary circulating form)

Background

25-hydroxyvitamin D (25OHD) is the predominant and most stable circulating form of vitamin D and is the preferred analyte to evaluate vitamin D status. The active hormone, 1,25-dihydroxyvitamin D, has a much shorter half-life and is used selectively for evaluating defects in vitamin D metabolism rather than routine status assessment. Vitamin D deficiency is commonly defined as serum 25OHD <20 ng/mL and is associated with rickets, osteomalacia, osteoporosis, and increased fracture risk; testing should be targeted to patients with relevant risk factors or clinical indications.

Policy Summary

PayerOscar Health

PolicyVitamin D Testing (coverage criteria for 25‑OH and 1,25‑dihydroxyvitamin D testing)

Policy CodePolicy N/A

Change TypeAdministrative — no material clinical changes

Effective DateOct 1, 2026

Last ReviewJun 16, 2026

Next Review DateJun 16, 2026

SourceLink

On This Page

see therapeutic criteria

Perioperative/bariatric surgery: Baseline and postoperative evaluation for vitamin D deficiency in patients undergoing Roux‑en‑Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion (with/without duodenal switch)

society recommendation (chunks 33)

Symptomatic or severe deficiency: Testing appropriate for symptomatic vitamin D deficiency (e.g., hypocalcaemia, bone disease) or very low baseline levels and when poor compliance or malabsorption is suspected; consider retesting 3–6 months after treatment initiation if indicatedretest >= 3 months

NHS, RACGP, Manchester guidance (chunk 36)

Assessment or monitoring of vitamin D status in patients with bone disease/osteoporosis, malabsorption, malnutrition, post‑bariatric surgery, altered calcium/phosphorus metabolism, transplant recipients, or on meds increasing vitamin D catabolism

Bone disease/osteoporosis and related conditions: Assessment or monitoring of vitamin D status in patients with bone disease or osteoporosis, malabsorption, malnutrition, post‑bariatric surgery, conditions altering calcium/phosphorus metabolism, organ transplant recipients, or when on medications that increase vitamin D catabolism.

Also indicated for symptomatic deficiency and very low baseline values.

Symptomatic vitamin D deficiency (e.g., hypocalcaemia or bone disease) — Repeat testing may be considered for monitoring after treatment

Symptomatic deficiency monitoring: Symptomatic vitamin D deficiency (e.g., hypocalcaemia or bone disease) — repeat testing may be considered for monitoring after treatment.

Manchester trust guidance supports repeat testing in symptomatic cases.

Malabsorption in a patient taking vitamin D — Repeat testing may be considered to assess adequacy of replacement

Malabsorption on replacement: Malabsorption in a patient taking vitamin D — repeat testing may be considered to assess adequacy of replacement therapy.

Per Manchester trust repeat-testing guidance.

Patients on oral anti-resorptive agents with low baseline vitamin D — Repeat testing may be considered

Anti-resorptive therapy monitoring: Patients on oral anti-resorptive agents with low baseline vitamin D — repeat testing may be considered to ensure sufficient levels prior to or during therapy.

Repeat testing allowed per Manchester trust when baseline was low.

Minimum repeat testing interval

Not within 3 months of the initial test

Preferred repeat testing intervalPreferably not within 6 months in most patients

Repeat-testing exceptionsAllowed for symptomatic deficiency, malabsorption on therapy, or patients on oral anti-resorptive agents with low baseline levels

Billing Rule

Procedure codes to report on claims

Use the specific procedure code that corresponds to the analyte and method performed: CPT 82306 for 25‑hydroxyvitamin D, CPT 82652 for 1,25‑dihydroxyvitamin D, or proprietary code 0038U for the referenced LC‑MS/MS microsample assay.

Bill with 82306 for total 25‑OH (including fractions when performed).
Bill with 82652 for 1,25‑dihydroxyvitamin D.
Bill with 0038U for the Sensieva™ Droplet LC‑MS/MS microsample assay.

Note

Therapy guidance — informational

Clinical guidance and public health recommendations (e.g., IOM) support routine dietary supplementation for many individuals, but this policy does not mandate or require specific therapy prior to testing; supplementation guidance is informational only.

IOM and trial reviews recommend maintaining serum 25OHD between ~20–40 ng/mL; policy does not impose step‑therapy drug rules.

Note

Empiric treatment alternative for asymptomatic high‑risk patients

Some guidance (Manchester NHS/Trust) recommends treating asymptomatic high‑risk individuals empirically with vitamin D supplementation without prior serum measurement; testing may be reserved for symptomatic individuals or those needing monitoring.

Recommendation: “Asymptomatic individuals at high risk of Vitamin D deficiency should be treated without measurement of Vitamin D and should be advised on the need for maintenance dose Vitamin D supplementation.”

Note

Testing may not be required prior to supplementation in asymptomatic high‑risk individuals

Guidance reiterates that asymptomatic high‑risk individuals may be treated with supplementation without measurement; therefore testing is not required in those cases unless clinical indications demand measurement or monitoring.

Policy note: testing may be avoided in favor of empiric supplementation to reduce unnecessary testing workload.

Documentation Required

Documentation and coding requirement for claims

Providers must submit accurate documentation of services performed and code claims according to industry standard coding/billing guidelines; failure to follow coding or billing guidance may result in claim denial or recoupment.

Follow industry coding resources (CPT, HCPCS, ICD‑10, UB, CMS NCCI) when submitting claims.
Inaccurate coding or documentation can lead to denial or claim recovery.

Documentation Required

Recommended supporting documentation to justify testing

When ordering or requesting repeat testing, document supporting clinical data: prior abnormal 25‑OH results within 6 months, relevant biochemical indicators (calcium, phosphorus, alkaline phosphatase, PTH), and the clinical rationale (e.g., malabsorption, bone disease, medications) to justify the test.

Include prior 25‑OH result if within 6 months and any abnormal biochemical indicators.
Document clinical context such as malabsorption, anti‑resorptive therapy, or symptomatic deficiency.

Billing Rule

Coding and assay regulatory documentation to include on claims

Include the specific CPT/HCPCS procedure code on claims (82306, 82652, or 0038U) and note the assay regulatory status when relevant (whether the laboratory test is an LDT and its CLIA high‑complexity classification).

Identify the exact code for the analyte/method performed on the claim.
If the lab uses an LDT, document that it is CLIA high‑complexity and any available validation details.

Denial Risk

Denial risk for non‑medical‑necessity or miscoding

Claims for vitamin D testing may be denied if the service does not meet the policy's authorization and medical necessity criteria or if services are not coded according to standard coding guidelines.

Tests without clinical indications listed in the policy or exceeding frequency limits risk denial.
Incorrect coding or failure to document medical necessity may lead to denial or recoupment.

Denial Risk

Unjustified test requests risk denial

A large retrospective study (32,363 tests) found a high proportion of vitamin D test requests were judged unjustified by medical criteria; requests lacking appropriate clinical indication are at risk for denial.

Study finding: many test requests were unjustified by clinical and biochemical criteria, supporting stricter documentation of indications.

Denial Risk

Repeat testing interval risk — potential denial for early repeats

Repeat 25‑OH testing performed within three months (and preferably within six months) of an initial test is not recommended by multiple guidance sources and may be considered unnecessary and subject to denial.

RACGP and Manchester NHS guidance state retesting should not occur within three months of starting replacement and preferably not within six months.

Biochemical indicators — laboratory abnormalities relevant to vitamin D assessment

Relevant biochemical indicatorsAlterations in serum or urine calcium and phosphorus

Alkaline phosphataseElevation (when not due to liver/growth) may indicate bone disease

Parathyroid hormonePTH outside reference range (14–72 pg/mL) is relevant

25-hydroxyvitamin D (25-OH) — key information

Analyte25-hydroxyvitamin D (25-OH)

CPT code82306 — Vitamin D; 25 hydroxy, includes fraction(s), if performed

RolePrimary analyte measured to assess vitamin D status

1,25-dihydroxyvitamin D — key information

Analyte1,25-dihydroxyvitamin D (active form)

CPT code82652 — Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed

Use caseMeasured in select clinical situations (defects in vitamin D metabolism); not for routine deficiency screening

Laboratory-developed test (LDT) — definition and regulatory note

DefinitionLaboratory-developed test (LDT): a test developed and performed in-house by a laboratory

Regulatory statusRegulated under CLIA as high-complexity testing; may not be FDA-cleared or approved

DocumentationLabs performing LDTs must validate assays and comply with CLIA requirements